News and Trends 13 Nov 2017 Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […] November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2017 Roche Partners with French Startup to Diagnose Septic Shock In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […] November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Nov 2017 Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin The ‘butterfly child’ who lost 80% of his skin has been successfully treated. The boy is now able to go to school and enjoy life with family and friends. A medical team from the Ruhr-Universität Bochum’s burn unit and the Center for Regenerative Medicine at the University of Modena have treated a boy suffering from […] November 9, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […] November 8, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 Phase I Results are in for Swedish Biotech’s Cancer Antibody Alligator Bioscience has reported promising results from a Phase I study, where its candidate has been well tolerated in patients with late-stage solid tumors. Alligator Bioscience, located in Lund, Sweden, develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2017 British Researchers Find Thought Police to Treat Neurological Disorders Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […] November 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […] November 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 German Biotech Teams Up with BioNTech to Boost Antibody Development MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation using its own sophisticated platform. On the back of a highly productive agreement signed in 2013, BioNTech, Europe’s largest privately held biopharma, has moved to agree […] November 6, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech Update (6/11/2017): ADV7103 has maintained its efficacy in a 6-month extension of the Phase III study. In 79% of the patients, the blood bicarbonate levels were kept within the normal range after 6 months of treatment, further supporting its push to become the first treatment for the disease on the market. Originally published 11/9/2017 Advicenne has […] November 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Get your Company Ready for the EU’s New Data Protection Law With the beginning of summer next year, not only temperatures will rise, but possibly also temperaments, as the European Union’s new data protection law takes effect. The highly tightened measures to protect personal data will mean that companies worldwide have a lot of adjusting to do. Like most new regulations, the General Data Protection Regulation […] November 6, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email